Article
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
European journal of gastroenterology & hepatology - 1 Dec 2021
El Kassas Mohamed, Abdeen Nermeen, Omran Dalia, Alboraie Mohamed, Salaheldin Mohamed, Eltabbakh Mohamed, Farghaly Rasha, Emadeldeen Mohammed, Afify Shimaa, Sweedy Ahmad, Ghalwash Ahmed, Abbass Amr, Ezzat Sameera, Tahoon Marwa, ELshazly Helmy M, Hamdy Hassan, Omar Heba
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV)-related decompensated cirrhosis is a severe life-threatening illness. The safety of direct-acting antivirals (DAAs) has opened a gate of hope for that subgroup of patients who were previously contraindicated for interferon therapy. OBJECTIVE: We aimed at the investigation of the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.